EGFR-altered lung cancer therapy has emerged as a cornerstone with the use of osimertinib medication, a potent TKI.A major challenge remains with the emergence of drug resistance to this drug.The article analyzes drug resistance mechanisms to osimertinib medication, seeking to uncover the complex aspects behind the phenomenon and offer insights on potential treatment approaches.Several key routes can be categorized in osimertinib medication drug resistance mechanisms, including:The T790M EGFR mutation is one of the key routes in osimertinib medication drug resistance mechanisms.The MET gene amplification is another key pathway in osimertinib…
